Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trial.

Cancer survivorship Health-related quality of life Self-management Web-based intervention eHealth

Journal

Internet interventions
ISSN: 2214-7829
Titre abrégé: Internet Interv
Pays: Netherlands
ID NLM: 101631612

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 11 09 2020
revised: 22 02 2021
accepted: 07 07 2021
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 18 8 2021
Statut: epublish

Résumé

The web-based self-management application Oncokompas was developed to support cancer survivors to monitor health-related quality of life and symptoms (Measure) and to provide tailored information (Learn) and supportive care options (Act). In a previously reported randomised controlled trial (RCT), 68% of 655 recruited survivors were eligible, and of those 45% participated in the RCT. Among participants of the RCT that were randomised to the intervention group, 52% used Oncokompas as intended. The aim of this study was to explore reasons for not participating in the RCT, and reasons for not using Oncokompas among non-users, and the use and evaluation of Oncokompas among users. Reasons for not participating were assessed with a study-specific questionnaire among 243 survivors who declined participation. Usage was investigated among 320 participants randomised to the intervention group of the RCT via system data and a study-specific questionnaire that was assessed during the 1 week follow-up (T1) assessment. Main reasons for not participating were not interested in participation in scientific research (40%) and not interested in scientific research and Oncokompas (28%). Main reasons for not being interested in Oncokompas were wanting to leave the period of being ill behind (29%), no symptom burden (23%), or lacking internet skills (18%). Out of the 320 participants in the intervention group 167 (52%) used Oncokompas as intended. Among 72 non-users, main reasons for not using Oncokompas were no symptom burden (32%) or lack of time (26%). Among 248 survivors that activated their account, satisfaction and user-friendliness were rated with a 7 (scale 0-10). Within 3 (IQR 1-4) sessions, users selected 32 (IQR 6-37) topics. Main reasons for not using healthcare options in Act were that the information in Learn was already sufficient (44%) or no supportive care needs (32%). Main reasons for not reaching or using Oncokompas were no symptom burden, no supportive care needs, or lack of time. Users selected many cancer-generic and tumour-specific topics to address, indicating added value of the wide range of available topics.

Identifiants

pubmed: 34401388
doi: 10.1016/j.invent.2021.100429
pii: S2214-7829(21)00069-5
pmc: PMC8350584
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100429

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

IMV-dL has received grants from the Dutch Cancer Society (KWF Kankerbestrijding), Pink Ribbon, the Netherlands Organization for Health Research and Development (ZonMW), the SAG Foundation–Zilveren Kruis Health Care Assurance Company, Danone Ecofund–Nutricia, Red-kite (distributor of eHealth tools), and Bristol-Myers Squibb, during the conduct of this study. CRL has received personal fees for global advisory board participation from MSD, during the conduct of this study. All other authors have no conflicts of interest.

Références

Eur Psychol. 2019;24(1):7-25
pubmed: 31496632
Eur J Cancer Care (Engl). 2009 May;18(3):223-47
pubmed: 19432917
J Clin Oncol. 2011 Apr 1;29(10):e277-8; author reply e279-80
pubmed: 21300932
J Med Internet Res. 2019 Jan 24;21(1):e10875
pubmed: 30679145
Psychooncology. 2008 Jul;17(7):690-8
pubmed: 18033733
Patient Educ Couns. 2016 Jul;99(7):1087-1098
pubmed: 26856778
J Clin Oncol. 2011 Mar 20;29(9):1216-20
pubmed: 21343558
J Multidiscip Healthc. 2020 Oct 27;13:1257-1281
pubmed: 33149597
J Clin Oncol. 2019 May 20;37(15):1326-1335
pubmed: 30925126
J Cancer Res Clin Oncol. 2017 Nov;143(11):2291-2299
pubmed: 28699035
Support Care Cancer. 2016 Jun;24(6):2445-53
pubmed: 26643072
J Natl Cancer Inst. 2021 May 4;113(5):523-531
pubmed: 32525530
Support Care Cancer. 2017 Dec;25(12):3775-3783
pubmed: 28702685
Lancet Oncol. 2020 Jan;21(1):80-94
pubmed: 31838009
Trials. 2017 May 22;18(1):228
pubmed: 28532439
Cancer. 2008 Jun 1;112(11 Suppl):2577-92
pubmed: 18428205
Br J Cancer. 2000 Jun;82(11):1783-8
pubmed: 10839291
Br J Cancer. 2013 Feb 19;108(3):736-7
pubmed: 23370207
Telemed J E Health. 2013 May;19(5):339-45
pubmed: 23289907
Med 2 0. 2012 Aug 14;1(2):e3
pubmed: 25075231
J Clin Oncol. 2014 Jan 20;32(3):199-205
pubmed: 24344222
J Clin Oncol. 2014 Aug 20;32(24):2662-8
pubmed: 25071099
Support Care Cancer. 2018 Feb;26(2):337-351
pubmed: 28921391
Support Care Cancer. 2015 Jun;23(6):1679-88
pubmed: 25424520
EJC Suppl. 2014 Jun;12(1):54-64
pubmed: 26217166
PLoS Med. 2009 Aug;6(8):e1000126
pubmed: 19688038
J Med Internet Res. 2018 May 01;20(5):e10235
pubmed: 29716883
Transl Behav Med. 2017 Jun;7(2):254-267
pubmed: 27966189
J Biomed Inform. 2017 Jul;71:31-48
pubmed: 28536062
BMC Cancer. 2015 Aug 11;15:580
pubmed: 26260318
J Cancer Surviv. 2021 Feb;15(1):77-86
pubmed: 32656739
Support Care Cancer. 2021 Feb;29(2):535-537
pubmed: 32671563
J Med Internet Res. 2012 Nov 14;14(6):e152
pubmed: 23151820
Lancet Oncol. 2006 Feb;7(2):141-8
pubmed: 16455478
Mol Oncol. 2019 Mar;13(3):624-635
pubmed: 30552794
Syst Rev. 2015 Nov 08;4:155
pubmed: 26547687
J Med Internet Res. 2013 Aug 20;15(8):e172
pubmed: 23963284
J Med Internet Res. 2017 Dec 06;19(12):e402
pubmed: 29212630
Health Informatics J. 2020 Dec;26(4):2811-2833
pubmed: 32731773
Int J Psychiatry Med. 2010;40(2):163-81
pubmed: 20848873
Trials. 2015 Jun 05;16:258
pubmed: 26044763
JMIR Res Protoc. 2017 Aug 07;6(8):e156
pubmed: 28784592
Evaluation (Lond). 2019 Jan;25(1):23-45
pubmed: 30705608
Health Aff (Millwood). 2015 Mar;34(3):431-7
pubmed: 25732493
Stud Health Technol Inform. 2015;216:142-7
pubmed: 26262027
BMC Med. 2020 Jan 20;18(1):6
pubmed: 31955710
Support Care Cancer. 2017 Apr;25(4):1323-1355
pubmed: 28058570
Semin Oncol. 2013 Dec;40(6):774-83
pubmed: 24331196

Auteurs

A van der Hout (A)

Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.
Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.

C F van Uden-Kraan (CF)

Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.
Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.

K Holtmaat (K)

Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.
Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.

F Jansen (F)

Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands.

B I Lissenberg-Witte (BI)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam, the Netherlands.

G A P Nieuwenhuijzen (GAP)

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.

J A Hardillo (JA)

Department of Otolaryngology and Head and Neck Surgery, Erasmus MC Cancer Centre, Erasmus Medical Center, Rotterdam, the Netherlands.

R J Baatenburg de Jong (RJ)

Department of Otolaryngology and Head and Neck Surgery, Erasmus MC Cancer Centre, Erasmus Medical Center, Rotterdam, the Netherlands.

N L Tiren-Verbeet (NL)

Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.

D W Sommeijer (DW)

Department of Internal Medicine, Flevoziekenhuis, Almere, the Netherlands.
Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands.

K de Heer (K)

Department of Internal Medicine, Flevoziekenhuis, Almere, the Netherlands.
Amsterdam UMC, University of Amsterdam, Department of Hematology, Amsterdam, the Netherlands.

C G Schaar (CG)

Department of Internal Medicine, Gelre ziekenhuis, Apeldoorn, the Netherlands.

R J E Sedee (RJE)

Department of Otolaryngology, Head and Neck Surgery, Haaglanden MC, The Hague, the Netherlands.

K Bosscha (K)

Department of Surgery, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.

M W M van den Brekel (MWM)

Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.

J F Petersen (JF)

Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.

M Westerman (M)

Department of Hematology, Northwest Clinics, Alkmaar, the Netherlands.

J Honings (J)

Department of Otorhinolaryngology - Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

R P Takes (RP)

Department of Otorhinolaryngology - Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

I Houtenbos (I)

Department of Hematology, Spaarne Gasthuis, Hoofddorp, the Netherlands.

W T van den Broek (WT)

Department of Surgery, St. Anna Hospital, Geldrop, the Netherlands.

R de Bree (R)

Department of Head and Neck Surgical Oncology, Utrecht University Medical Center, Utrecht, the Netherlands.

P Jansen (P)

Department of Surgery, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.

S E J Eerenstein (SEJ)

Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands.

C R Leemans (CR)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands.

J M Zijlstra (JM)

Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, the Netherlands.

P Cuijpers (P)

Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.

L V van de Poll-Franse (LV)

Department of Research, Netherlands Comprehensive Cancer Organisation, Eindhoven, the Netherlands.
Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, the Netherlands.
CoRPS - Center of Research on Psychological and Somatic Disorders, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands.

I M Verdonck-de Leeuw (IM)

Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, the Netherlands.
Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands.

Classifications MeSH